Literature DB >> 27660592

Treatment of Hepatitis C Virus Genotype 3 Infection.

Fred Poordad1.   

Abstract

Entities:  

Year:  2015        PMID： 27660592      PMCID： PMC4849525     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Jawad Ilyas; Zhigang Duan; Hashem B El-Serag
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

2.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Authors:  Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

Review 3.  Review article: HCV genotype 3 – the new treatment challenge.

Authors:  J Ampuero; M Romero-Gómez; K R Reddy
Journal:  Aliment Pharmacol Ther       Date:  2014-04       Impact factor: 8.171

4.  The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Authors:  Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim
Journal:  Ann Intern Med       Date:  2015-05-05       Impact factor: 51.598

5.  Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.

Authors:  Eric Lawitz; Fred Poordad; Diana M Brainard; Robert H Hyland; Di An; Hadas Dvory-Sobol; William T Symonds; John G McHutchison; Fernando E Membreno
Journal:  Hepatology       Date:  2015-01-30       Impact factor: 17.425

6.  All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Authors:  David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.